• Bleomycin A2 sulfate, EvoPure packaged and labeled.

click on thumbnail to zoom
SKU: B019

  Click 'Bulk Order' for 10 or more
Price: make selection(s)

Bleomycin A2 sulfate is one of two components found in the glycopeptide antibiotic bleomycin sulfate, a chemotherapeutic agent used for the treatment of Hodgkin's lymphoma. Bleomycin A2 and B2 are structurally similar and differ by a unique terminal amine group.

TOKU-E offers three forms of bleomycin: bleomycin sulfate (B005), bleomycin A2 sulfate, EvoPure® (B019), and bleomycin B2 sulfate, EvoPure® (B020). EvoPure® products are individual molecular fractions, most >99% pure.

    CAS Number


    Molecular Formula

    C55H84N17O21S3 · xH2SO4 (lot specific)

    Molecular Weight

    1415.55 (Free base)

    Mechanism of Action

    Bleomycin acts as an anticancer agent by causing single stranded breaks in DNA. The exact mechanism is not well defined however; it is thought to chelate metallic ions to decrease enzyme activity and stability. This effect is believed to cause enzymes to react with oxygen producing free radicals which create single stranded breaks in deoxyribose sugar.

    Storage Conditions


    Tariff Code



    Cancer Applications

    Common treatment for Hodgkin's lymphoma.

    Plant Biology Applications

    Bleomycin binds to specific DNA sequences and causing single-stranded and double-stranded DNA breaks, causing cell death. As a result Bleomycin can be used as gene selection agent. Only plantlets possessing a newly introduced resistance gene (Ble) in combination with a random gene of interest will be able to survive a bleomycin application as is shown in tobacco by Miki and co-workers (2003).





    White or off-white crystalline powder


    Streptomyces verticillus



    Loss on Drying


Technical Data

HPLC Chromatogram Showing Ultra High, Single Fraction Purity of Bleomycin A2 Sulfate, EvoPure®

Bleomycin A2 sulfate, EvoPure



    Kole, C., Michler C.H., Abbott A.G. and Hall C.T. 2010. Transgenic Crop Plants: Volume 1: Principles and Development. Springer

    Miki B., McHugh S., 2003 Selectable marker genes in transgenic plants: applications, alternatives and biosafety. Journal of Biotechnology 107 (2004) 193–232.

    Dorr, R. T. "Bleomycin Pharmacology: Mechanism of Action and Resistance, and Clinical Pharmacokinetics." Seminars in Oncology 19.2 (1992): 3-8. Ncbi.gov. Web. 11 Sept. 2012.

    "Monographs: Pharmaceutical Substances: Bleomycini Hydrochloridum - Bleomycin Hydrochloride." The International Pharmacopoeia. N.p., n.d. Web. 16 Jan. 2013.

Other Items In This Category